Radiopharmaceuticals in neurological and psychiatric disorders
SourceCurrent Clinical Pharmacology
Google Scholar check
MetadataShow full item record
The development of functional brain nuclear medicine techniques and their application in the investigation of neuropsychiatric disorders, have contributed significantly in the illumination of the underlying pathophysiological processes of these disorders. Furthermore, Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) brain studies provide information in early diagnosis, differential diagnosis, development of new drugs, and monitoring the response to therapeutic management. SPECT and PET brain imaging require the use of radiopharmaceuticals that cross the intact Blood Brain Barrier (BBB). Such radiotracers have been used in regional Cerebral Blood Flow (rCBF) SPECT and PET imaging and brain metabolism imaging with PET; these are well established methods in the diagnosis and management of various cerebral vascular diseases (e.g. stroke, dementia, epilepsy). Advances in radiotracer chemistry have resulted in the development of molecular imaging which represents the molecular and cellular processes of neurochychiatric diseases. SPECT and PET molecular imaging has become available for the study of acetylcholinergic, dopaminergic and serotonergic systems, as well as for benzodiazepine and opioid receptors, with promising results. More studies are needed to validate the role of molecular imaging in the clinical practice of neuropsychiatric disorders. © 2008 Bentham Science Publishers Ltd.
Showing items related by title, author, creator and subject.
Effects of CCR5-Δ32, CCR2-64I, and SDF-1 3′ a alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data Ioannidis, J. P. A.; Rosenberg, P. S.; Goedert, J. J.; Ashton, L. J.; Benfield, T. L.; Buchbinder, S. P.; Coutinho, R. A.; Eugen-Olsen, J.; Gallart, T.; Katzenstein, T. L.; Kostrikis, Leontios G.; Kuipers, H.; Louie, L. G.; Mallal, S. A.; Margolick, J. B.; Martinez, O. P.; Meyer, L.; Michael, N. L.; Operskalski, E.; Pantaleo, G.; Rizzardi, G. P.; Schuitemaker, H.; Sheppard, H. W.; Stewart, G. J.; Theodorou, I. D.; Ullum, H.; Vicenzi, E.; Vlahov, D.; Wilkinson, D.; Workman, C.; Zagury, J. -F; O'Brien, T. R. (2001)Background: Studies relating certain chemokine and chemokine receptor gene alleles with the outcome of HIV-1 infection have yielded inconsistent results. Objective: To examine postulated associations of genetic alleles ...
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial Skarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, Anna; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C.; Pectasides, Dimitrios; Gogas, H.; Aravantinos, Gerasimos; Pavlidis, Nicholas; Arapantoni, P.; Skarlos, Dimosthenis V.; Fountzilas, George (2012)Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate ...
Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx Pentheroudakis, George; Nicolaou, I.; Kotoula, V.; Fountzilas, E.; Markou, K.; Eleftheraki, A. G.; Fragkoulidi, A.; Karasmanis, I.; Tsigka, A.; Angouridakis, N.; Vlachtsis, K.; Nikolaou, A.; Pavlidis, Nicholas; Fountzilas, George (2012)Angiogenesis is active in localised laryngeal squamous cell carcinoma. We assessed relative messenger RNA (mRNA) and immunohistochemical (IHC) expression of Vascular Endothelial Growth Factors (VEGF) A, B, C, their receptors ...